First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.

ABSTRACT:

Background

Guidelines recommend sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists as second-line therapy for patients with type 2 diabetes. Expanding their use as first-line therapy has been proposed but the clinical benefits may not outweigh their costs.

Objective

To evaluate the lifetime cost-effectiveness of a strategy of first-line SGLT2 inhibitors or GLP1 receptor agonists.

Design

Individual-level Monte Carlo-based Markov model.

Data sources

Randomized trials, Centers for Disease Control and Prevention databases, RED BOOK, and the National Health and Nutrition Examination Survey.

Target population

Drug-naive U.S. patients with type 2 diabetes.

Time horizon

Lifetime.

Perspective

Healt

SUBMITTER: Choi JG 

PROVIDER: S-EPMC10155215 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature